Intraocular inoculation of antigens induces anterior chamber-associated immune deviation (ACAID), which is mediated by development of regulatory T cells in response to antigen-presenting cells (APC) pre-conditioned by intraocular transforming growth factor-b (TGF-b). In this study, we examined the involvement of T-cell co-stimulatory molecules in this process. To mimic the intraocular APC, thioglycollate-elicited peritoneal exudate cells (PEC) were pre-treated with TGF-b in vitro. Expression of CD80, CD86, OX40 ligand (OX40L) and CD70 was analyzed by flow cytometry. Contribution of these molecules to co-stimulatory activity of TGF-b-treated PEC on antigen-stimulated T-cell proliferation and cytokine production was determined by inhibition with blocking antibodies in vitro. Contribution of CD80 and CD86 to induction of ACAID was determined by the administration of blocking antibodies at intraocular antigen inoculation in vivo. TGF-b-treated PEC expressed CD80 and CD86 but not OX40L or CD70. Antigen-stimulated T cells proliferated and produced IL-10, but not IFN-c, in response to co-stimulation by TGF-b-treated PEC, which was abrogated by blocking antibodies against CD80 and CD86. Induction of regulatory cells mediating ACAID was abolished by in vivo blockade of CD80 and CD86. The present results indicated that CD80 and CD86 play a critical role in induction of ACAID, possibly by co-stimulating expansion and IL-10 production of regulatory T cells in response to TGF-b-conditioned APC.
Introduction
Various antigens, ranging from allografts to soluble heterologous proteins, injected into the anterior chamber (AC) of the eye elicit a uniquely deviated systemic immune response, termed anterior chamber-associated immune deviation (ACAID), which is characterized by the suppression of inflammatory T h 1 responses, including delayed-type hypersensitivity (DTH) and production of complement-fixing antibodies (1) (2) (3) (4) . ACAID arises because intraocular antigen-presenting cells (APC), inducing macrophages and dendritic cells, capture antigens injected into the AC, migrate through the trabecular meshwork into the blood and then traffic preferentially to the spleen, where they induce antigen-specific regulatory T cells suppressing T h 1 responses (3, 4) .
Transforming growth factor-b (TGF-b), abundant in aqueous humor of the AC, plays a critical role in the induction of ACAID by conditioning the intraocular APC to acquire ACAID-inducing potential (5, 6) . Thus, conventional APC such as macrophages in thioglycollate-elicited peritoneal exudate cells (PEC) can also acquire the ACAID-inducing potential after TGF-b treatment in vitro (6) . We recently demonstrated that antigen presentation by the TGF-b-treated PEC stimulated naive Tcells to produce IL-4 and IL-10, but not IFN-c, possibly due to the inability to produce IL-12 (7, 8) .
Activation and differentiation of T cells requires not only cytokines but also co-stimulatory molecules expressed on APC in addition to the engagement of antigen-specific TCR. CD28 is the most extensively characterized co-stimulatory receptor on T cells, which interacts with CD80 and CD86 on APC (9) . In addition, some members of the tumor necrosis factor receptor superfamily, including CD27, OX40 and 4-1BB, also transmit a co-stimulatory signal for T-cell proliferation and cytokine production (10) . In the present study, we determined the expression of CD80, CD86, CD27 ligand (CD70), OX40 ligand (OX40L) and 4-1BB ligand (4-1BBL) on the TGF-b-treated PEC and their role in co-stimulating the expansion and IL-10 production of T cells in vitro. We also found a critical contribution of CD80 and CD86 to the induction of regulatory T cells mediating ACAID in vivo.
Methods

Animals and cell lines
Male BALB/c mice were purchased from Charles River Japan (Atsugi, Japan). Mice transgenic for the ovalbumin peptide 323-339 (OVA 323-339 )-specific and I-A d -restricted DO11.10 TCR on a RAG2 ÿ/ÿ background were generously supplied by S. Koyasu (Keio University, Tokyo, Japan) and bred and maintained in the Oriental Yeast Co. (Tokyo, Japan). All mice were 6-to 7-week old at the start of experiments and kept under specific pathogen-free condition during the experiments. The hybridomas producing mAbs against MHC class II (M5/114), HSA (J11d), B220 (RA3-3A1) and CD8 (3.155) were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium containing 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mg ml ÿ1 penicillin and streptomycin and 50 lM 2-Mercaptoethanol (2-ME).
Antibodies
Purified anti-mouse CD16/32 (2.4G2) and CD3 (145-2C11) mAbs, FITC-conjugated anti-mouse CD4 (RM4-4), CD8 (53-6.7), B220 (RA3-6B2), CD11b (M1/70) and NK1.1 (PK136) mAbs, PE-conjugated anti-mouse CD80 (16-10A1), CD86 (GL1) and CD70 (FR70) mAbs, isotype-matched control mouse IgGs and PE-labeled streptavidin were purchased from BD Pharmingen (San Diego, CA, USA). Rabbit anti-asialo GM1 antibody was purchased from Wako Biochemicals (Osaka, Japan). Purified and biotinylated anti-mouse CD80 (RM80, rat IgG2a), CD86 (PO.3, rat IgG2b), CD70 (FR70, rat IgG2b), OX40L (RM134L, rat IgG2b) and 4-1BBL (TKS-1, rat IgG2a) mAbs were prepared as described previously (11) (12) (13) (14) . Control rat IgG was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Culture medium
RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 mM HEPES, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 100 U ml ÿ1 penicillin, 100 lg ml ÿ1 streptomycin, 1 3 10 ÿ5 M 2-ME, 0.1% BSA, 1 lg ml ÿ1 iron-free transferrin, 10 ng ml ÿ1 linoleic acid, 0.3 ng ml ÿ1 Na 2 Se and 0.2 mg ml ÿ1 Fe(NO 3 ) 3 was used for the preparation of PEC and coculture of T cells and PEC.
Preparation of CD4 + T cells
Spleens were removed from normal BALB/c mice or RAG2 ÿ/ÿ DO11.10 TCR-transgenic mice and pressed through nylon mesh to produce a single-cell suspension. RBCs were lysed with Tris-NH 4 Cl. T cells were enriched by passage through nylon wool column (Wako Biochemicals). CD4 + T cells were purified by treatment with a mixture of hybridoma supernatants (M5/114, J11d, RA3-3A1 and 3.155), rabbit anti-asialo GM1 antibody (100 lg ml ÿ1 ) and low-tox rabbit complement (Cedarlane, Hornby, Ontario, Canada). Splenic T cells were purified by passage through nylon wool column (Wako Biochemicals) and the treatment with a mixture of hybridoma supernatants (anti-MHC class II, anti-HSA and anti-B220) and low-tox rabbit complement (Cedarlane). The purity was >95% CD4 + as determined by flow cytometry. 
Preparation of PEC
Flow cytometric analysis
Cells (5 3 10 5 ) were first pre-incubated with unlabeled anti-CD16/32 mAb to avoid non-specific binding of mAbs to Fcc receptor and then incubated with a saturating amount of FITC-, PE-and biotin-labeled mAbs. After washing with PBS twice, the cells were incubated with PE-labeled streptavidin for biotinylated mAb. After washing with PBS twice, the stained cells (live-gated on the basis of forward-and side-scatter profiles and propidium iodide exclusion) were analyzed on a FACSCalibur (BD Biosciences, San Jose, CA, USA) and data were processed using the CellQuest program (BD Biosciences).
Induction of ACAID and DTH assay
Induction and evaluation of ACAID were performed essentially as described previously (15) . Briefly, BALB/c mice received an inoculation of OVA (Sigma-Aldrich, 50 lg per 2 ll) dissolved in PBS into the AC of the right eye. Some groups of the mice received i.p. administration of 300 lg each of anti-CD80 mAb and anti-CD86 mAb or 600 lg of control rat IgG on the same day. All these mice then received a subcutaneous injection of OVA (100 lg per 100 ll) emulsified in CFA (Life Technologies, Grand Island, NY, USA) into the nape of the neck 3 weeks later. After 1 week, the mice were challenged with an intradermal injection of OVA (200 lg per 10 ll) into the right ear pinnae. After 24 h, the ear swelling was measured using a micrometer (Mitutoyo, MTI Corporation, Paramus, NJ, USA).
Local adoptive transfer (LAT) assay
Development of regulatory T cells was tested in the LAT assay essentially as described previously (16) . Briefly, splenocytes prepared from BALB/c mice that had received intraocular inoculation of OVA (50 lg per 2 ll) and i.p. administration of anti-CD80 mAb and anti-CD86 mAb (300 lg each) or control IgG (600 lg) 14 days before were prepared as the regulator cells. Effector cells were prepared from lymph node (LN) of BALB/c mice that had been subcutaneously immunized with OVA (100 lg per 100 ll) in CFA 7 days before. Stimulator cells were prepared by pulsing PEC with OVA (100 lg ml ÿ1 ) overnight. Effector cells (5 3 10 6 ), stimulator cells (1 3 10 6 ) and regulatory cells (5 3 10 6 ) were re-suspended in 10 ll of HBSS and inoculated into the ear pinnae of naive BALB/c mice. Ear swelling was measured at 24 h. Spleen cells from naive mice were used as a negative control for regulatory cells.
Statistical analysis
Data were analyzed by using analysis of variance and t test. P values <0.05 were considered significantly different.
Results
Expression of co-stimulatory molecules on TGF-b-treated PEC
We first examined the expression of CD80, CD86, OX40L, CD70 and 4-1BBL on TGF-b-treated PEC by flow cytometry.
PEC were prepared from normal BALB/c mice that had received thioglycollate i.p. 3 days before and then treated overnight with or without TGF-b. Representative results are shown in Fig. 1 . Both freshly isolated CD11b + PEC and cultured PEC expressed CD80 and CD86 at equivalent levels, irrespectively of the TGF-b treatment. The expression of OX40L was slightly detected on PEC after overnight culture without TGF-b, but not on PEC cultured with TGF-b. CD70 was expressed on freshly isolated CD11b + PEC and overnightcultured PEC at a comparable level but was down-regulated by the TGF-b treatment. 4-1BBL was not detectable on either freshly isolated PEC or cultured PEC with or without TGF-b (data not shown). These results indicated that the TGF-b treatment down-regulated the expression of OX40L and CD70, while preserving the expression of CD80 and CD86, on PEC.
Co-stimulation of CD4 + T cells by CD80 and CD86 on TGF-b-treated PEC
We next examined the contribution of CD80, CD86, OX40L and CD70 expressed on untreated or TGF-b-treated PEC to the costimulation of naive T cells. Naive CD4 + T cells were purified from the spleen of normal BALB/c mice and stimulated with anti-CD3 mAb in the presence of untreated or TGF-b-treated PEC. Blocking mAbs against CD80, CD86, OX40L and CD70 were added to the culture to determine the contribution of these molecules. Proliferative response and production of IFN-c and IL-10 were assessed after 48 h. Results of representative experiments are shown in Fig. 2 . In the absence of PEC, naive T cells were unable to proliferate or produce IFN-c or IL-10 in response to anti-CD3 stimulation. The anti-CD3-stimulated T-cell proliferation co-stimulated with TGF-b-treated PEC was comparable with that of untreated PEC (Fig. 2a) . The costimulation by untreated PEC was not significantly inhibited by a single mAb against CD80, CD86, OX40L or CD70. In contrast, the co-stimulation by TGF-b-treated PEC was significantly inhibited by anti-CD86 mAb alone, suggesting the predominant contribution of CD86. As shown in Fig. 2(b) , untreated, but not TGF-b-treated, PEC co-stimulated IFN-c production by anti-CD3-stimulated T cells as we previously reported (7, 8) . The co-stimulation by untreated PEC was significantly inhibited by any of the mAbs against CD80, CD86, OX40L and CD70, suggesting substantial contribution of all these molecules. As shown in Fig. 2(c) , TGF-b-treated PEC costimulated IL-10 production more efficiently than untreated PEC. The co-stimulation by both untreated and TGF-b-treated PEC was significantly inhibited by mAbs against CD80 or CD86.
To further clarify the contribution of CD80 and CD86, we examined the effect of a combination of anti-CD80 and anti-CD86 mAbs (Fig. 3) . When co-stimulated by untreated PEC, the combined anti-CD80/CD86 mAbs did not significantly inhibit the proliferative response and only partially inhibited the IFN-c and IL-10 production (Fig. 3) . In contrast, when costimulated by TGF-b-treated PEC, proliferation was markedly inhibited and IL-10 production was totally abolished by the combination of anti-CD80 and anti-CD86 mAbs (Fig. 3a and c) . The similar contributions of CD80/86 on co-stimulation of TGFb-treated PEC were also observed when TGF-b-treated PEC were pulsed with protein antigen and used as APC. Results of representative experiments are shown in Fig. 4 . In this experiment, naive CD4 + T cells were purified from DO11.10 TCR-transgenic mice of which T cells possess OVA-specific TCR and stimulated with OVA-pulsed TGF-b-treated or -untreated PEC. Proliferative response was assessed after 48 h and production of IFN-c and IL-10 was assessed after 72 h. When DO11.10 TCR-transgenic T cells were stimulated with OVA-pulsed and untreated PEC, the combined anti-CD80/ CD86 mAbs did not significantly inhibit the proliferative response, or the IL-10 production, and only partially inhibited the IFN-c production (Fig. 4) . In contrast, when DO11.10 TCRtransgenic T cells were stimulated with OVA-pulsed and TGF-b-treated PEC, both proliferative responses and IL-10 production were notably inhibited by the combination of anti-CD80 and anti-CD86 mAbs (Fig. 4a and c) , which were compatible with the results of the experiments using anti-CD3 mAb.
These results indicated that the co-stimulation by untreated PEC was only partially dependent on CD80 and CD86, but that by TGF-b-treated PEC was predominantly mediated by CD80 and CD86.
Critical contribution of CD80 and CD86 to induction of regulatory cells by intraocular inoculation of antigen
Given the critical contribution of CD80 and CD86 to the costimulation of T-cell expansion and IL-10 production by TGFb-treated PEC in vitro (Figs 3 and 4) , we next explored the involvement of CD80 and CD86 in the induction of regulatory cells by intraocular antigen inoculation in vivo. We employed the LAT assay (16) to determine the development of regulatory cells. LN cells from BALB/c mice that had been subcutaneously primed with OVA/CFA were used as the DTH effector. OVA-pulsed PEC were used as the stimulator. Splenocytes from BALB/c mice that had received an intraocular inoculation of OVA and an i.p. administration of anti-CD80/CD86 mAbs or control IgG 14 days before were used as the regulator. As shown in Fig. 5 , co-injection of OVA-primed LN cells as the effector with OVA-pulsed PEC (stimulator) and naive splenocytes (regulator) induced a substantial level of DTH response as compared with naive LN cells as the effector. This DTH response was significantly suppressed by the co-injection of splenocytes from intraocularly OVA-inoculated and control IgG-treated mice as the regulator. Importantly, this suppression was totally abrogated by the anti-CD80/CD86 mAb treatment. These results suggested that CD80 and CD86 played a critical role in the induction of regulatory cells by intraocular inoculation of OVA.
Critical contribution of CD80 and CD86 to induction of ACAID
We finally examined the contribution of CD80 and CD86 to the induction of ACAID by intraocular inoculation of antigen. Thus, BALB/c mice were intraocularly inoculated with OVA and i.p. administered with anti-CD80/CD86 mAbs or control IgG. Three weeks later these mice were subcutaneously immunized with OVA/CFA and then ear challenged with OVA 1 week later. As shown in Fig. 6 , ACAID was induced in the control IgG-treated mice as manifested by a marked suppression of DTH response. Notably, this suppression was totally abrogated in the anti-CD80/CD86 mAb-treated mice. These results suggested that CD80 and CD86 played an essential role in the induction of ACAID by intraocular inoculation of OVA.
Discussion
In this study, we first compared the expression of costimulatory molecules on TGF-b-treated PEC with that on TGF-b-untreated PEC. While CD80 and CD86 were constitutively expressed on freshly isolated CD11b + PEC and not affected by overnight treatment with TGF-b, OX40L and CD70 were down-regulated by the TGF-b treatment (Fig. 1) . We previously reported that the TGF-b treatment down-regulated CD40 on PEC, resulting in the inability to produce IL-12 upon interaction with CD40 ligand expressed on activated T cells and thus to co-stimulate IFN-c production by naive T cells (7). Since both OX40L and CD70 were involved in the costimulation of IFN-c production by TGF-b-untreated PEC (Fig.  2b) , the down-regulation of OX40L and CD70 might be also responsible for the inability of TGF-b-treated PEC to costimulate IFN-c production. It is notable that co-stimulation by TGF-b-untreated PEC was largely CD80/CD86 independent (Figs 2-4) . This might be due to redundant co-stimulatory functions of CD80/CD86, OX40L and CD70 expressed on the untreated PEC, since we previously demonstrated that OX40L and CD70 could costimulate naive T cells in a CD28-independent manner (17) . Alternatively, some other co-stimulatory molecules, such as B7h engaging inducible co-stimulator (ICOS) on T cells (18, 19) , might play a predominant role. Further studies are needed to address these possibilities.
In contrast to the TGF-b-untreated PEC, co-stimulatory function of TGF-b-treated PEC was mostly dependent on CD80 and CD86 (Figs 3 and 4) . This seems to be due to the down-regulation of other co-stimulatory molecules by the TGFb treatment (Fig. 1) . Our present results indicate that TGFb-treated PEC are not inert but actively induce the expansion and/or differentiation of IL-10-producing regulatory T cells via CD80/CD86 co-stimulation.
In ACAID, the intraocular injection of antigens prevents the DTH response, but enhances antibody production, to specific antigens. The results of a number of studies suggest that two types of regulatory cells, CD4 + and CD8 + T cells, exist in mice with ACAID, although each mediates its inhibitory effect on different stages of the immune response; the CD4 + population impairs the induction, whereas the CD8 + population inhibits the expression, phase of the DTH response (16, 20) . Because mice with ACAID are unable to mount a DH response to intraocularly injected antigen but do produce antibodies, it is possible that cells producing T h 2-type cytokines are induced, leading to a T h 2 cytokine-mediated down-regulation of the T h 1 In vivo blockade of CD80 and CD86 at intraocular antigen inoculation inhibited the induction of regulatory cells (Fig. 5 ) and the development of ACAID (Fig. 6) . Given the in vitro data indicating that the co-stimulatory function of TGF-b-treated PEC, which mimic ACAID-inducing ocular APC, to induce proliferation and IL-10 production of naive T cells was mostly dependent on CD80 and CD86 (Figs 3 and 4) , these results suggest that CD80 and CD86 play a critical role in the induction of ACAID by co-stimulating the expansion and/or differentiation of IL-10-producing regulatory T cells in response to ocular APC pre-conditioned by intraocular TGF-b.
It has been extensively characterized that CD80 and CD86 play a pivotal role in generating effector T-cell responses. Paradoxically, however, recent studies have revealed that constitutively expressed CD80 and CD86 on resting APC function to suppress T-cell responses and maintain selftolerance by sustaining a population of regulatory T cells (22, 23) . Our present results further substantiate such an immunoregulatory function of CD80 and CD86, which contribute to maintain ocular immune privilege by co-stimulating the development of IL-10-producing regulatory cells mediating ACAID. Since TGF-b-conditioned APC are also abundant in mucosal tissues, a similar mechanism may also be relevant to the induction and maintenance of mucosal tolerance. transforming growth factor-b Fig. 6 . Involvement of CD80 and CD86 in induction of ACAID. BALB/c mice were injected with OVA intraocularly and anti-CD80 and anti-CD86 mAbs or control IgG i.p. Three weeks later these mice were immunized subcutaneously with OVA plus CFA. One week later their ear pinnae were challenged with OVA. Positive controls were immunized with OVA and CFA 7 days before the intrapinnae challenge with OVA. Naive mice were challenged with OVA as the negative control. Ear-swelling responses were measured 24 h after challenge. Data are represented as the mean 6 SE of five mice in each group. Similar results were obtained in two independent experiments. *P < 0.05.
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